From the Department of Neurological and Psychiatric Sciences, University of Florence, Florence, Italy.
Ataxia with vitamin E deficiency is a recessive autosomal neurodegenerative disorder resembling the Friedreich ataxia phenotype but is due to mutations in the α-tocopherol transfer protein (TTPA) gene. In a recent article, we described a patient with ataxia carrying reduced serum vitamin E levels and showing CTA/CTG expansions of 320 triplet repeats in the SCA8 gene.
To perform a screening of the TTPA gene in the patient and to evaluate the effects of treatment with vitamin E on the patient's neurologic disturbances.
Patient and Methods
We performed a single-strand conformation polymorphism and nucleotide sequence analysis of the 5 exons of the TTPA gene in the patient's family members.
The results indicated the patient to be a compound heterozygote for 2 mutations (in exon 3), each transmitted by one of the 2 parents, yielding a nonfunctional protein.
We describe for the first time, to our knowledge, a mutated form of the TTPA gene in a patient also carrying an expansion in the SCA8 gene. The lack of improvement in the patient's symptoms on supplementation with α-tocopherol suggests that the SCA8 mutations may act in the neurodegeneration process, worsening the neurologic signs caused by the vitamin E deficit, and it could be speculated that the co-occurrence of mutant alleles for 2 distinct loci may influence the clinical course of the disease.
WE RECENTLY reported1 a clinical and genetic analysis of spinocerebellar ataxia type 8 (SCA8) in Italian patients. In particular, we described a patient with ataxia (PN-1 family) carrying reduced serum vitamin E levels and showing CTA/CTG expansions of 320 triplet repeats in the SCA8 gene, inherited via maternal transmission. In this patient, we recently identified a mutated form of the α-tocopherol transfer protein (TTPA) gene, which has been reported2 to cause ataxia with vitamin E deficiency (AVED). Vitamin E (α-tocopherol) has an important antioxidant role and its plasma levels are regulated by oral intake and absorption and transfer into circulating lipoproteins secreted by the liver. The α-tocopherol transfer protein seems to regulate this latter step.3
Ataxia with vitamin E deficiency is a recessive autosomal neurodegenerative disorder characterized by progressive ataxia, areflexia, decreased proprioceptive and vibratory sensations, and dysarthria. The clinical symptoms of vitamin E deficiency resemble the Friedreich ataxia (FA) phenotype but the two can be distinguished in terms of genetic defect, consisting in AVED of mutations in the TTPA gene located on 8q13.4 Patients with AVED usually have low levels (<1 µg/mL) of vitamin E, but the clinical symptoms show at least some improvement when supplemented with α-tocopherol at an early stage of the disease.
A 30-year-old woman belonging to the PN-1 family had a clinical history of progressive ataxia. Her early development was normal but at the age of 7 years she started to experience gait disturbances and was diagnosed as having FA without cardiac abnormalities and diabetes. Cerebral magnetic resonance imaging revealed pure cerebellar atrophy without clinical and radiologic signs of brainstem involvement. By the age of 17 years, she had become wheelchair bound, and genetic studies revealed no specific FA GAA expansion in the FRDA gene. Laboratory tests revealed a low serum vitamin E concentration (0.3 µg/mL [0.012 µmol/L]; normal range, 5.0-15.2 µg/mL [0.215-0.654 µmol/L]); thus, the patient was treated with vitamin E at a dose of 300 mg, 3 times per day. However, after a follow-up period of 1 year, the patient's neurologic disturbances showed no clinical improvement.
We performed a single-strand conformation polymorphism and nucleotide sequence analysis of the 5 exons of the TTPA gene in the PN-1 patient's family members (Figure 1). Informed consent was obtained for the genetic analysis after the nature of the procedure had been fully explained. The results indicated the patient to be a compound heterozygote for 2 mutations (in exon 3), carrying both the 400 C/T mutation (paternally inherited) and the 513 TT-insertion (maternally inherited), each transmitted by one of the 2 parents. The genetic defects characterizing our patient are truncating mutations (400 C/T, causes an Arg/ter substitution; 513 TT-insertion causes a frameshift with the insertion of 4 aberrant amino acids, leading to a shortened product), yielding a nonfunctional protein.
Pedigree of PN-1 family. The filled symbol represents the affected individual, while unaffected SCA8 (spinocerebellar ataxia type 8) expansion carriers are indicated with an internal dot. The arrow indicates the proband. The actual age is shown beneath the symbols in parentheses. For each individual, the number of SCA8 repeats and the kind of mutation in the TTPA (α-tocopherol transfer protein) gene are indicated.
Both parents did not show any neurologic alterations despite having the 2 TTPA gene mutations in heterozygosity; however, they decided to start taking the same vitamin E supplementation. The healthy brother of the proband, whom we examined more recently, was found to carry an expansion of 169 triplet repeats in the SCA8 gene and have the heterozygous mutation (400 C/T, paternally inherited) in the TTPA gene. He had normal serum vitamin E levels.
About 20 different mutations in the TTPA gene have been reported5 worldwide in AVED families of different ethnic origins (North African, European, North American, and Japanese). Compound heterozygotes for different mutations have been described in a few families, but to our knowledge, no patient carrying a combination of the 400 C/T and 513 TT-insertion mutations has ever been reported. To our knowledge, this is the first time a mutated form of the TTPA gene in a patient also carrying an expansion in the SCA8 gene has been described.
The lack of improvement in the patient's symptoms on supplementation with α-tocopherol suggests that the SCA8 mutations may act in the neurodegeneration process, worsening the neurologic signs caused by the vitamin E deficit. In addition, it could be speculated that the co-occurrence of mutant alleles for 2 distinct loci may influence the clinical course of the disease.
Since previous evidence6 suggests that extremely long (>250 CTA/CTG repeats) expansions in the SCA8 gene are not necessarily always pathogenic, we hypothesize that the 320 repeat expansion identified in our patient might play a role in her neurologic dysfunction only because the patient is carrying another genetic defect, in the α-tocopherol gene, leading to ataxia. This hypothesis is strengthened by the fact that the mother and brother of this proband, although carrying, respectively, a 105 and 169 CTA/CTG repeat expansion in the SCA8 gene and 1 mutated allele in the TTPA gene, show no evidence of neurologic alterations. This case confirms the uncertain role of CTA/CTG expansions in SCA8 pathogenesis. The reported low penetrance of SCA8 among patients with ataxia (<1%), the wide variability in disease expression, and the presence of this expansion in nonataxic subjects as well (eg, in 2 patients with Alzheimer disease7), suggest that mutations in another gene, as well as other epigenetic factors, should significantly influence the ataxia phenotype in families carrying an SCA8 mutation. These results suggest that, in our patient, vitamin E deficiency at a genetic level together with the previously detected SCA8 expansion may play an important role in the pathogenesis of spinocerebellar degeneration.
Accepted for publication May 9, 2002.
Author contributions: Study concept and design (Drs Nacmias, Forleo, and Sorbi); acquisition of data (Drs Cellini, Piacentini, and Sorbi); analysis and interpretation of data (Drs Cellini, Nacmias, Forleo, Tedde, Bagnoli, Ciantelli, and Sorbi); drafting of the manuscript (Drs Piacentini, Nacmias, Bagnoli, Ciantelli, and Sorbi); critical revision of the manuscript for important intellectual content (Drs Cellini, Nacmias, Forleo, and Tedde); statistical expertise (Drs Nacmias and Tedde); obtained funding (Drs Piacentini and Sorbi); administrative, technical, and material support (Drs Cellini, Forleo, Bagnoli, and Ciantelli); study supervision (Drs Piacentini, Nacmias, Forleo, and Sorbi).
This research was supported by grant 000.000163.ST74 from Consiglio Nazionale delle Ricerche, Rome, Italy.
Corresponding author and reprints: Prof Sandro Sorbi, MD, Department of Neurological and Psychiatric Sciences, University of Florence, Viale Morgagni 85, 50134 Florence, Italy (e-mail: email@example.com).
Thank you for submitting a comment on this article. It will be reviewed by JAMA Neurology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 9
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.